NYMOX

IRVINE, Calif., July 25, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (the “Company”) is pleased to announce today important new long-term clinical trial results from the Company's 146 patient NX03-0040 NYMOZARFEX (TM) U.S.…

<!-- Name:DistributionId Value:8750168 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4577 -->…

IRVINE, Calif., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to announce today that a new formal submission has been made by the Company in Europe for Fexapotide Triflutate…

Article content IRVINE, Calif., May 23, 2022 (GLOBE NEWSWIRE) — Nymox Pharmaceutical Corporation (NASDAQ: NYMX) reports today that it has received a Refusal to File (“RTF”) letter from FDA on Friday May 20th at 2:48 pm EST, with regard to…

IRVINE, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to announce today that it has submitted the Company’s New Drug Application (NDA) to the FDA for Fexapotide…

HASBROUCK HEIGHTS, N.J., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to report today a one-month update to shareholders as a follow-up to the September communication. The…